Hong Kong Baptist University (HKBU) and Shanghai Industrial Investment (Holdings) Co Ltd (SIIC) have announced a strategic partnership aimed at leveraging their respective strengths to advance the proposed establishment of Hong Kong’s third medical school, contributing to Hong Kong’s development into an international hub for medical training, research, and innovation.
SIIC and its subsidiary Shanghai Pharmaceuticals Holding Co Ltd (SPH) will also actively participate in HKBU’s newly founded Frontier Translational Medical Research Institute, infusing fresh momentum into medical education, innovative research, and technology translation in Hong Kong and the Greater Bay Area (GBA).
Supported by an extensive network of local and GBA hospitals, medical professionals, and international organisations, HKBU has submitted a proposal to the Hong Kong SAR Government to establish the third medical school in Hong Kong, focusing on innovative education to train high-quality doctors and meet the clinical needs of a rapidly ageing society through the research institute’s focus on innovation, technology translation, and application.
Professor Alex Wai, President and Vice-Chancellor of HKBU, said, “Our collaboration will focus on several core areas, including supporting the establishment of the new medical school, promoting research and innovation, integrating healthcare in the GBA, building a collaborative platform, and exploring other areas of mutual interest, and thereby collectively advancing the development of frontier translational medical research.”
Yang Qiuhua, Vice President of SIIC cum Chairman and Executive Director of Shanghai Pharmaceutical Group, stated, “We believe that this partnership will invigorate medical education, heritage and internationalisation of traditional Chinese medicine in Hong Kong and the GBA, and will foster closer ties in the traceability and innovations of Chinese medicine among Hong Kong, the GBA, and the Yangtze River Delta, aiding the development of our national healthcare.”
